Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma

BACKGROUND: Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve (TIC) of arterial phase on contrast-enhanced ultrasound (CEUS) as early imagin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuorda, Hidekatsu, Abe, Tamami, Fujiwara, Yudai, Okamoto, Takuya, Yonezawa, Miki, Sato, Hiroki, Endo, Kei, Oikawa, Takayoshi, Sawara, Kei, Takikawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Prospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529888/
https://www.ncbi.nlm.nih.gov/pubmed/31148907
http://dx.doi.org/10.3748/wjg.v25.i19.2365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529888/
https://www.ncbi.nlm.nih.gov/pubmed/31148907
http://dx.doi.org/10.3748/wjg.v25.i19.2365

Ejemplares similares